Genotype-specific MRD interpretation improves stratification in paediatric acute lymphoblastic leukaemia

Genotype-specific MRD interpretation improves stratification in paediatric acute lymphoblastic leukaemia

<strong>Purpose</strong> Minimal residual disease (MRD) and genetic abnormalities are important risk factors for outcome in acute lymphoblastic leukemia. Current risk algorithms dichotomize MRD data and do not assimilate genetics when assigning MRD risk, which reduces predictive accuracy...

ver descrição completa

Detalhes bibliográficos
Main Authors:	O'Connor, D, Enshaei, A, Bartram, J, Hancock, J, Harrison, C, Hough, R, Samarasinghe, S, Schwab, C, Vora, A, Wade, R, Moppett, J, Moorman, A, Goulden, N
Formato:	Journal article
Publicado em:	American Society of Clinical Oncology 2017

Registos relacionados

Cytogenetic-specific heterogeneity in the kinetics of minimal residual disease (MRD) clearance in childhood acute lymphoblastic leukaemia (ALL)
Por: Moorman, A, et al.
Publicado em: (2007)

Use of Minimal Residual Disease Assessment to Redefine Induction Failure in Pediatric Acute Lymphoblastic Leukemia.
Por: O'Connor, D, et al.
Publicado em: (2017)

A novel integrated cytogenetic and genomic classification refines risk stratification in pediatric acute lymphoblastic leukemia.
Por: Moorman, A, et al.
Publicado em: (2014)

Post-Remission MRD Kinetics in Children with Acute Lymphoblastic Leukaemia Receiving Augmented BFM Consolidation Compared with Other Regimens Results of the Medical Research Council Trial UKALL2003.
Por: Cutting, R, et al.
Publicado em: (2008)

Outcome of Down syndrome associated acute lymphoblastic leukaemia treated on a contemporary protocol.
Por: Patrick, K, et al.
Publicado em: (2014)

Outcome of Down syndrome associated acute lymphoblastic leukaemia treated on a contemporary protocol
Por: Patrick, K, et al.
Publicado em: (2014)

Delineation of Risk Factors in Paediatric Acute Lymphoblastic Leukaemia with Favourable Cytogenetics
Por: Moorman, A, et al.
Publicado em: (2012)

Post-remission MRD kinetics in children with acute lymphoblastic leukaemia receiving augmented BFM consolidation compared with other regimens: update of results of the Medical Research Council Trial UKALL2003
Por: Cutting, R, et al.
Publicado em: (2009)

Cytogenetic-specific heterogeneity in the kinetics of minimal residual disease (MIRD) clearance in childhood lymphoblastic leukaemia (ALL)
Por: Moorman, A, et al.
Publicado em: (2008)

Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial.
Por: Vora, A, et al.
Publicado em: (2014)

Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): A randomised controlled trial
Por: Vora, A, et al.
Publicado em: (2014)

Down Syndrome is a significant risk factor for infectious deaths in childhood acute lymphoblastic leukaemia: a retrospective analysis of the infectious deaths on UKALL 2003
Por: O'Connor, D, et al.
Publicado em: (2014)

Outcome for children and young people with Early T-cell precursor acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003
Por: Patrick, K, et al.
Publicado em: (2014)

Outcome for children and young people with Early T-cell precursor acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003.
Por: Patrick, K, et al.
Publicado em: (2014)

Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial.
Por: Vora, A, et al.
Publicado em: (2013)

Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial
Por: Vora, A, et al.
Publicado em: (2013)

Incidence and outcome of pancreatitis in children and young adults with acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003
Por: Samarasinghe, S, et al.
Publicado em: (2013)

Incidence and outcome of pancreatitis in children and young adults with acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003.
Por: Samarasinghe, S, et al.
Publicado em: (2013)

PCR-based MRD testing for acute lymphoblastic leukaemia in India
Por: Rubina Islam, et al.
Publicado em: (2017-01-01)

Infection-related mortality in children with acute lymphoblastic leukemia: an analysis of infectious deaths on UKALL2003.
Por: O'Connor, D, et al.
Publicado em: (2014)

Comparison of clinical significance of MRD as determined by IgH genescanning or allele specific probing in childhood ALL.
Por: Moppett, J, et al.
Publicado em: (2002)

Profile of Steroid Toxicity During Maintenance Treatment in Teenage and Young Adult (TYA) Patients with Acute Lymphoblastic Leukaemia (ALL)
Por: Tomlins, J, et al.
Publicado em: (2012)

Improved Outcome for Children and Young Adults with T-Cell Acute Lymphoblastic Leukaemia (ALL): Results of the United Kingdom Medical Research Council (MRC) Trial UKALL 2003
Por: Vora, A, et al.
Publicado em: (2008)

Efficacy and Toxicity of Pegylated Asparaginase in the Treatment of Children and Young Adults with Acute Lymphoblastic Leukaemia: Results of the United Kingdom Medical Research Council (MRC) Trial UKALL 2003
Por: Vora, A, et al.
Publicado em: (2008)

Incidence and Outcome of Osteonecrosis in Children and Young Adults with Acute Lymphoblastic Leukaemia Treated on a Dexamethasone Containing Protocol: Results of the Medical Research Council UK Trial ALL 2003
Por: Vora, A, et al.
Publicado em: (2008)

Risk-directed treatment intensification significantly reduces the risk of relapse among children and adolescents with acute lymphoblastic leukemia and intrachromosomal amplification of chromosome 21: a comparison of the MRC ALL97/99 and UKALL2003 trials.
Por: Moorman, A, et al.
Publicado em: (2013)

The impact of risk stratification by early bone-marrow response in childhood lymphoblastic leukaemia: results from the United Kingdom Medical Research Council trial ALL97 and ALL97/99.
Por: Mitchell, C, et al.
Publicado em: (2009)

Adolescents with acute lymphoblastic leukaemia: outcome on UK national paediatric (ALL97) and adult (UKALLXII/E2993) trials.
Por: Ramanujachar, R, et al.
Publicado em: (2007)

Late relapsing childhood lymphoblastic leukaemia.
Por: Frost, L, et al.
Publicado em: (1997)

UKALL 2003, A Randomised Trial Investigating Treatment Reduction for Children and Young Adults with Minimal Residual Disease Defined Low Risk Acute Lymphoblastic Leukaemia
Por: Vora, A, et al.
Publicado em: (2010)

UKALL 2003, A Randomised Trial Investigating Treatment Reduction for Children and Young Adults with Minimal Residual Disease Defined Low Risk Acute Lymphoblastic Leukaemia
Por: Vora, A, et al.
Publicado em: (2010)

UKALL 2003, A Randomised Trial Investigating Treatment Reduction for Children and Young Adults with Minimal Residual Disease Defined Low Risk Acute Lymphoblastic Leukaemia
Por: Vora, A, et al.
Publicado em: (2010)

PROSPECTIVE EVALUATION OF QUALITY OF LIFE (QOL) IN CHILDREN TREATED IN UKALL 2003 FOR ACUTE LYMPHOBLASTIC LEUKAEMIA (ALL): A COHORT STUDY
Por: Eiser, C, et al.
Publicado em: (2012)

Three distinct subgroups of hypodiploidy in acute lymphoblastic leukaemia.
Por: Harrison, C, et al.
Publicado em: (2004)

Late relapsing childhood acute lymphoblastic leukaemia.
Por: Frost, L, et al.
Publicado em: (1998)

Intraocular relapse of childhood acute lymphoblastic leukaemia.
Por: Somervaille, T, et al.
Publicado em: (2003)

Variables affecting kinetics of minimal residual disease clearance in children with lymphoblastic leukaemia; Results of the United Kingdom Medical Research Council (UK MRC) protocols ALL97, ALL97/99 and ALL2003.
Por: Vora, A, et al.
Publicado em: (2005)

Thiopurine methyltransferase genotype-phenotype discordance and thiopurine active metabolite formation in childhood acute lymphoblastic leukaemia.
Por: Lennard, L, et al.
Publicado em: (2013)

Treatment of infants with lymphoblastic leukaemia: results of the UK Infant Protocols 1987-1999.
Por: Chessells, J, et al.
Publicado em: (2002)

Molecular mechanisms involved in chemoresistance in paediatric acute lymphoblastic leukaemia
Por: Stanković Tatjana, et al.
Publicado em: (2008-01-01)